We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
GLP·Agonists Editor's Pick

Corrections

Corrections

Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.

Every correction made to GLP Agonists is logged here with date, the original error, and the verified replacement. We do not silently edit pages to fix factual mistakes — when something material changes, we say so.

How to report an error

If you spot a factual error, a stale price, an outdated regulatory claim, or a citation that fails verification, email glpagonists@gmail.com with:

  • The URL of the page in question
  • The specific claim or sentence in question (quoted verbatim)
  • The primary source that disagrees (FDA, state board, clinical trial, etc.)

We acknowledge corrections within seven business days. Verified corrections are published within 14 business days with a dated note appended to the page and an entry added to this log.

What counts as a correction

Three categories, each handled differently:

  • Factual corrections. A wrong number, a wrong drug name, a wrong FDA-status claim, a wrong date. These get a corrections-log entry and a visible "Corrected on [date]" note on the page.
  • Pricing updates. Providers change pricing constantly. A pricing update is not a correction unless the original number was wrong on the date it was published. Routine pricing refreshes are logged in the page's "Last updated" line, not here.
  • Clarifications. Material context added or wording sharpened to prevent misreading. These get an inline "Clarification" note but typically do not appear in this log.

Corrections log

DatePageCorrection
May 20, 2026 Site-wide Pricing for compounded semaglutide and tirzepatide unified across all pages to canonical ranges ($145–$165/mo sema; $186–$215/mo tirz). Earlier references using single-point figures ($165, $199, $215) updated to ranges to better reflect actual published provider pricing across plan tiers.
May 20, 2026 llms.txt llms.txt updated to canonical pricing ranges (was: "$145–$165/mo flat-rate compounded semaglutide ($186–$215/mo for compounded tirzepatide)"). Editor's-pick description rewritten to remove unsourced claims about Forbes ranking, member count, and average weight loss until primary-source verification.
May 20, 2026 news.html Added four 2026 news entries covering FDA orforglipron approval, state board pharmacy actions, FDA shortage-resolution timeline implementation, and CMS coverage policy updates. Each entry sourced to a primary regulatory document.
May 20, 2026 Provider reviews (all) "Last fact-checked" attribution line added to every provider page identifying Dr. Adam Kennah, MD as clinical reviewer and the date of last review. This makes our reviewer firewall verifiable on a per-page basis.

Pages that have been materially corrected

This list will populate as substantive content corrections are made. As of May 20, 2026, no provider review has had a factual claim (price, drug name, mechanism, FDA status, contraindication) corrected since launch. Date-stamp refreshes, pricing-range normalization, and structural improvements are tracked above but are not categorized as factual corrections.

Last updated: May 20, 2026.